Медицинский совет (Aug 2022)
Therapy experience in alopecia after COVID-19
Abstract
The coronavirus infection (COVID-2019) caused by SARS-CoV-2 continues to be studied, the virus mutates, new strains differing from the previous ones by rapid spread appear. Due to the difficult epidemiological situation around the world, the long-term course of the pandemic, doctors of various disciplines are increasingly facing its consequences. 25% of patients have various types of alopecia following infection. Suppression of some growth factors due to the collapse of the immune privilege, local and systemic inflammation, oxidative stress, tissue hypoxia, microvascular insufficiency manifested by persistent capillary spasm influence hair loss. The article presents data from the analysis, out-patient medical records of patients aged 19 to 60 years who sought advice from the Ekaterininskaya clinic network with complaints of hair loss and past history of confirmed coronavirus infection. Due to the variety of trigger factors and multifaceted pathogenetic mechanisms of influence on the hair follicle in coronavirus infection, it is more appropriate to use drugs with a complex mechanism of action for the treatment. The patients received a complex drug for the treatment of alopecia, 1 tablet three times a day for 2 months, and a peptide lotion for cutaneous use with active ingredients, which activate cellular metabolism in hair follicles, encourage the hair follicles to switch to the active growth phase. A positive result during treatment was achieved in 92% of patients. Good tolerability, absence of side effects allow us to administer the drugs we use in a range of therapeutic measures in patients with diffuse hair thinning following coronavirus infection, both in monotherapy and in combination with other drugs.
Keywords